Career upgrade: Learn practical AI skills for better jobs and higher pay.
Level up
PracticeVideosBlogFlashcardsEspañol
All Practice Exams

100+ Free BCIDP Practice Questions

Pass your Board Certified Infectious Diseases Pharmacist exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately
100+ Questions
100% Free
1 / 100
Question 1
Score: 0/0

Which clinical decision support system (CDSS) alert is most valuable for antimicrobial stewardship within the electronic health record?

A
B
C
D
to track
Same family resources

Explore More BPS Pharmacy Specialty Certifications

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

BCPS

Practice Questions2 blogs

BCACP

Practice Questions1 blog

BCOP Board Certified Oncology Pharmacist

Practice Questions1 blog

BCCCP

Practice Questions

BCCP Board Certified Cardiology Pharmacist

Practice Questions

BCEMP Board Certified Emergency Medicine Pharmacist

Practice Questions

More From This Family

Videos and articles for deeper review.

ArticleBCACP Exam Guide 2026: Ambulatory Care Pharmacy Prep8 min readArticleFREE BCOP Exam Guide 2026: Oncology Pharmacist Prep10 min readArticleFREE BCPS Exam Guide 2026: BPS Pharmacotherapy Cert20 min readArticleFREE NABP FPGEE Exam Guide + Pass Plan (2026)20 min read
2026 Statistics

Key Facts: BCIDP Exam

150

Total Questions

125 scored + 25 unscored (Oct 2025 specs)

3h 45m

Exam Time

BPS BCIDP specifications (2025)

60%

Therapeutics Domain

Largest content domain

$600

Exam Fee

BPS fee schedule (2026)

7 years

Certification Valid

BPS recertification cycle

4 years

Practice Requirement

50%+ time in ID pharmacy

The BCIDP exam uses 150 items (125 scored + 25 unscored) administered over 3 hours 45 minutes with BPS scaled scoring (200-800). The Oct 2025 content outline weights Pathophysiology and Epidemiology at 18%, Therapeutics and Patient Management at 60%, and Professional Practice at 22%. BPS charges $600 for initial certification and $300 for retakes. Eligibility requires an active pharmacist license plus 4 years ID practice (50%+ time), PGY1 + 2 additional years, or a PGY2 in ID Pharmacy. Certification is valid for 7 years.

Sample BCIDP Practice Questions

Try these sample questions to test your BCIDP exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A patient with MRSA bacteremia has a vancomycin trough of 8 mcg/mL after 48 hours of therapy. Based on current IDSA/ASHP/SIDP vancomycin guidelines, what is the recommended approach?
A.Continue current dosing as the trough is within therapeutic range
B.Target an AUC/MIC ratio of 400-600 using Bayesian software or first-order PK calculations
C.Increase the dose to achieve a trough of 20-25 mcg/mL
D.Discontinue vancomycin and switch to oral therapy
Explanation: The 2020 IDSA/ASHP/SIDP revised vancomycin guidelines recommend targeting an AUC/MIC ratio of 400-600 (assuming a vancomycin MIC of 1 mcg/mL) using Bayesian software or first-order pharmacokinetic calculations for serious MRSA infections. Trough-only monitoring (targeting 15-20 mcg/mL) has been replaced because it was associated with higher nephrotoxicity without improved efficacy. AUC-guided dosing optimizes efficacy while minimizing toxicity.
2Which beta-lactam antibiotic has the broadest spectrum of activity against gram-negative organisms including most Pseudomonas aeruginosa and many carbapenem-resistant Enterobacterales (CRE)?
A.Ampicillin-sulbactam
B.Ceftazidime-avibactam
C.Cefazolin
D.Amoxicillin-clavulanate
Explanation: Ceftazidime-avibactam combines a third-generation cephalosporin with a novel non-beta-lactam beta-lactamase inhibitor (avibactam) that inhibits Class A (including KPC), Class C (AmpC), and some Class D (OXA-48) beta-lactamases. It covers Pseudomonas aeruginosa and many CRE producing KPC carbapenemases. However, it does NOT cover metallo-beta-lactamase (MBL)-producing organisms (e.g., NDM, VIM, IMP).
3Which mechanism of antimicrobial resistance is responsible for MRSA (methicillin-resistant Staphylococcus aureus)?
A.Production of extended-spectrum beta-lactamases (ESBLs)
B.Acquisition of mecA gene encoding altered penicillin-binding protein PBP2a
C.Efflux pump upregulation
D.Ribosomal methylation
Explanation: MRSA resistance is mediated by the mecA gene (carried on the SCCmec mobile genetic element), which encodes an altered penicillin-binding protein called PBP2a (also known as PBP2'). PBP2a has low affinity for nearly all beta-lactam antibiotics, rendering the entire class ineffective regardless of beta-lactamase inhibitor addition. This is why MRSA requires non-beta-lactam agents like vancomycin, daptomycin, or linezolid.
4A hospitalized patient develops watery diarrhea and tests positive for Clostridioides difficile infection (CDI) toxin. This is the first episode with no severity markers. What is the recommended first-line treatment per IDSA/SHEA 2021 guidelines?
A.Oral metronidazole 500 mg three times daily for 10 days
B.Oral fidaxomicin 200 mg twice daily for 10 days
C.Oral vancomycin 500 mg four times daily for 14 days
D.Intravenous vancomycin 1 g every 12 hours
Explanation: The 2021 IDSA/SHEA focused update recommends fidaxomicin 200 mg PO BID for 10 days as the preferred first-line treatment for initial non-severe CDI. Fidaxomicin has a narrower spectrum that better preserves the normal gut microbiota and has lower CDI recurrence rates compared to oral vancomycin. Oral vancomycin 125 mg QID for 10 days is an acceptable alternative if fidaxomicin is unavailable.
5What is the primary pharmacodynamic parameter that predicts efficacy for beta-lactam antibiotics?
A.Peak-to-MIC ratio (Cmax/MIC)
B.Area under the curve to MIC ratio (AUC/MIC)
C.Time above MIC (%T>MIC)
D.Trough concentration
Explanation: Beta-lactam antibiotics exhibit time-dependent killing, meaning their efficacy correlates with the percentage of the dosing interval that the free (unbound) drug concentration exceeds the MIC (%fT>MIC). For cephalosporins, the target is typically 60-70% fT>MIC, while for carbapenems it is approximately 40% fT>MIC. This is why prolonged or continuous infusions of beta-lactams are used to maximize %fT>MIC, particularly for organisms with higher MICs.
6A patient with HIV has a CD4 count of 75 cells/mm³ and presents with ring-enhancing brain lesions on MRI. What is the most likely diagnosis and empiric treatment?
A.Cryptococcal meningitis; amphotericin B plus flucytosine
B.Cerebral toxoplasmosis; pyrimethamine plus sulfadiazine plus leucovorin
C.Progressive multifocal leukoencephalopathy; antiretroviral therapy alone
D.CMV encephalitis; ganciclovir
Explanation: Ring-enhancing brain lesions in an AIDS patient with CD4 <100 cells/mm³ are most commonly caused by Toxoplasma gondii cerebral abscess. First-line treatment is pyrimethamine plus sulfadiazine plus leucovorin (folinic acid to prevent pyrimethamine-induced bone marrow suppression). Treatment is typically given for 6 weeks for acute infection, followed by chronic suppressive therapy until immune reconstitution with ART achieves sustained CD4 >200.
7Which antifungal class works by inhibiting the synthesis of beta-(1,3)-D-glucan, a critical component of the fungal cell wall?
A.Azoles (e.g., fluconazole, voriconazole)
B.Polyenes (e.g., amphotericin B)
C.Echinocandins (e.g., caspofungin, micafungin, anidulafungin)
D.Flucytosine
Explanation: Echinocandins (caspofungin, micafungin, anidulafungin) inhibit beta-(1,3)-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Since mammalian cells lack cell walls, echinocandins have an excellent safety profile. They are fungicidal against Candida species and fungistatic against Aspergillus. They lack activity against Cryptococcus, Mucorales, and Fusarium because these organisms have different cell wall compositions.
8A 65-year-old patient presents with community-acquired pneumonia requiring ICU admission. Blood cultures grow Streptococcus pneumoniae. Per ATS/IDSA guidelines, what is the recommended empiric regimen for severe CAP?
A.Azithromycin monotherapy
B.Beta-lactam (ceftriaxone or ampicillin-sulbactam) plus a macrolide or respiratory fluoroquinolone
C.Vancomycin plus piperacillin-tazobactam
D.Trimethoprim-sulfamethoxazole monotherapy
Explanation: ATS/IDSA 2019 guidelines recommend combination therapy for severe CAP requiring ICU admission: a beta-lactam (ceftriaxone 2 g IV daily or ampicillin-sulbactam 3 g IV q6h) PLUS either a macrolide (azithromycin) or a respiratory fluoroquinolone (levofloxacin or moxifloxacin). Combination therapy targets typical pathogens (S. pneumoniae, H. influenzae) and atypical organisms (Legionella, Mycoplasma). If risk factors for MRSA or Pseudomonas exist, additional coverage is added.
9Which aminoglycoside dosing strategy is preferred for once-daily (extended-interval) dosing to maximize bactericidal activity while minimizing nephrotoxicity?
A.Low-dose continuous infusion over 24 hours
B.High single daily dose targeting peak concentration 8-10 times the MIC
C.Divided doses every 4 hours to maintain constant drug levels
D.Fixed 1 mg/kg dose regardless of patient weight
Explanation: Extended-interval (once-daily) aminoglycoside dosing administers a high single daily dose (e.g., gentamicin/tobramycin 5-7 mg/kg) to achieve peak concentrations 8-10 times the MIC, maximizing concentration-dependent killing and the post-antibiotic effect. The drug-free interval allows for renal tubular cell recovery, reducing nephrotoxicity. Hartford nomogram or similar validated protocols are used to adjust dosing intervals based on drug levels.
10A patient with candidemia has Candida glabrata growing from blood cultures. The isolate is fluconazole-resistant but echinocandin-susceptible. What is the recommended treatment?
A.Fluconazole 800 mg loading then 400 mg daily
B.An echinocandin (e.g., micafungin 100 mg IV daily)
C.Oral itraconazole 200 mg twice daily
D.Amphotericin B deoxycholate 0.6 mg/kg/day
Explanation: For candidemia caused by fluconazole-resistant C. glabrata, IDSA 2016 guidelines recommend an echinocandin (caspofungin 70 mg load then 50 mg daily, micafungin 100 mg daily, or anidulafungin 200 mg load then 100 mg daily) as first-line therapy. Echinocandins are fungicidal against Candida and have excellent activity against C. glabrata. Treatment duration is at least 14 days from the first negative blood culture, plus removal of central venous catheters when feasible.

About the BCIDP Exam

The BCIDP certification validates advanced knowledge in infectious diseases pharmacy, including antimicrobial pharmacotherapy, stewardship, and infection prevention. The Oct 2025 exam specifications define 150 items (125 scored + 25 unscored) across three domains: Pathophysiology and Epidemiology (18%), Therapeutics and Patient Management (60%), and Professional Practice (22%).

Questions

150 scored questions

Time Limit

3 hours 45 minutes

Passing Score

Scaled (200-800, criterion-referenced)

Exam Fee

$600 (Board of Pharmacy Specialties (BPS))

BCIDP Exam Content Outline

18%

Pathophysiology and Epidemiology of Infections

Causes of infectious diseases (bacterial, viral, fungal, parasitic), microbiology testing and diagnostics, pathogen resistance, and immunologic response

60%

Therapeutics and Patient Management

Patient assessment, pharmacotherapy for infections by organ system (respiratory, skin, cardiovascular, bone/joint, CNS, GI, urologic, STIs, HIV), treatment outcomes and monitoring

22%

Professional Practice

Antimicrobial stewardship, infection prevention, public health, quality management, clinical informatics, and literature evaluation

How to Pass the BCIDP Exam

What You Need to Know

  • Passing score: Scaled (200-800, criterion-referenced)
  • Exam length: 150 questions
  • Time limit: 3 hours 45 minutes
  • Exam fee: $600

Keys to Passing

  • Complete 500+ practice questions
  • Score 80%+ consistently before scheduling
  • Focus on highest-weighted sections
  • Use our AI tutor for tough concepts

BCIDP Study Tips from Top Performers

1Dedicate 60% of study time to therapeutics: antimicrobial selection by infection type, PK/PD optimization, and adverse effects
2Know IDSA guidelines for major infections: pneumonia, UTI, SSTI, endocarditis, meningitis, osteomyelitis, and CDI
3Master antimicrobial resistance mechanisms: MRSA (mecA/PBP2a), ESBL (CTX-M), CRE (KPC, NDM), and VRE (vanA/vanB)
4Study HIV antiretroviral therapy: initial regimens, opportunistic infection prophylaxis thresholds, and drug interactions
5Review stewardship metrics and interventions: DOT, antibiogram development, de-escalation, IV-to-oral switch

Frequently Asked Questions

How many questions are on the BCIDP exam?

The BCIDP exam contains 150 total questions: 125 scored items and 25 unscored (pretest) items. Candidates cannot distinguish scored from unscored items during the exam.

How long is the BCIDP exam?

The BCIDP exam allows 3 hours and 45 minutes of testing time, effective with the October 2025 examination specifications update.

What score do I need to pass the BCIDP exam?

BPS uses scaled scoring on a 200-800 scale with a criterion-referenced passing standard. The passing score is determined by the BPS Specialty Council through a modified Angoff method, not a fixed percentage.

How much does the BCIDP exam cost?

The initial BCIDP certification application fee is $600. The retake fee is $300. Annual certification maintenance fees of $125 apply during years 1-6 of the 7-year certification cycle.

What are the BCIDP eligibility requirements?

Eligibility requires: (1) ACPE-accredited PharmD, (2) active pharmacist license, and (3) either 4 years ID practice (50%+ time), PGY1 + 2 additional years ID practice, or completion of a PGY2 residency in Infectious Diseases Pharmacy.

How should I prepare for the BCIDP exam in 2026?

Focus on the 60% therapeutics domain. Study IDSA/SHEA treatment guidelines for major infection types, master antimicrobial PK/PD optimization, and review antimicrobial stewardship strategies and resistance mechanisms.